NeoGenomics (US:NEO) — Company Overview, News & Financial Data
NeoGenomics is a lab specializing in genetic testing for cancer, offering extensive services across the U.S. to personalize treatment.
NeoGenomics
NeoGenomics (NASDAQ:NEO) is a specialized laboratory focused on genetic testing for cancer diagnosis, prognosis, and treatment planning. The company operates through a network of labs across the United States, offering a wide range of testing services, including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, molecular genetics, and next-generation sequencing. NeoGenomics aims to support personalizing cancer care through its comprehensive testing solutions, working closely with pathologists, oncologists, academic centers, and pharmaceutical companies. Their projects often involve developing new tests and technologies to stay at the forefront of precision medicine in oncology, with the objective of enhancing patient outcomes through tailored treatment approaches.
Snapshot
Operations
Products and/or services of NeoGenomics
- Comprehensive oncology testing services, offering a full suite of molecular diagnostic tests.
- Pharma Services, providing support for drug development and clinical trials.
- NeoTYPE Cancer Profiles, targeted sequencing panels for precise cancer diagnosis and treatment planning.
- MultiOmyx, a proprietary technology for high-definition immunohistochemistry analysis.
- Informatics services, utilizing data analytics for personalized treatment recommendations.
- Liquid biopsy tests, offering non-invasive cancer detection and monitoring solutions.
NeoGenomics executive team
- Mr. Anthony P. ZookCEO & Director
- Mr. Warren StonePresident & COO
- Mr. Jeffrey S. Sherman M.B.A.Chief Financial Officer
- Ms. Elizabeth A. FloegelChief Digital & Information Officer
- Ms. Alicia C. OlivoExecutive VP of Business Development, General Counsel & Corporate Secretary
- Mr. Gregory D. AunanSenior VP & Chief Accounting Officer
- Ms. Kendra SweeneyVice President of Investor Relations & Communications
- Mr. Clarence Cooper Esq.Vice President of Compliance & Privacy
- Mr. Gary PassmanChief People & Culture Officer
- Mr. Kareem M. SaadHead of Strategy, Business Development & Transformation